On the fly News and insights, exclusive to thefly.com


Puma Biotechnology

$7.30 /

-0.34 (-4.45%)


Puma Biotechnology falls after Bernie Sanders calls out 20% price hike

Puma Biotechnology (PBYI) increased the price of its breast cancer treatment Nerlynx by 20% in nine months, Ed Silverman of STAT News reported yesterday. Today, Presidential candidate and Senator Bernie Sanders responded to a STAT reporter asking if anybody will notice with a tweet saying, "I noticed, and I'm pretty damn sure patients with breast cancer and their families will notice too." Shares of Puma Biotechnology are down 4.5%, or 35c, to $7.30 in late morning trading. Reference Link

PBYI Puma Biotechnology
$7.30 /

-0.34 (-4.45%)

Fly Intel: Top five analyst downgrades
10/08/19 Goldman Sachs
Puma Biotechnology downgraded to Sell from Neutral at Goldman Sachs
08/09/19 Barclays
Puma Biotechnology price target lowered to $9 from $21 at Barclays
05/29/19 Goldman Sachs
Puma Biotechnology price target lowered to $24 from $29 at Goldman Sachs

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.